Bristol-Myers Squibb Company (BMY) has disclosed a new risk, in the Environmental / Social category.
Bristol-Myers Squibb Company confronts escalating risks associated with environmental, social, and governance (ESG) expectations and the complexities of related reporting obligations. The intensifying regulatory focus on climate change policies, sustainability, and equitable practices necessitates increased compliance and legal costs, diverting significant time and resources. Despite efforts to meet these dynamic requirements, inconsistencies or stakeholder disapproval of the company’s ESG targets could lead to reputational damage, potential litigation, and adverse business impacts. The company’s reliance on third-party data and performance further compounds the uncertainty surrounding its ESG initiatives.
Overall, Wall Street has a Moderate Buy consensus rating on BMY stock based on 5 Buys, 1 Sell and 9 Holds.
To learn more about Bristol-Myers Squibb Company’s risk factors, click here.
Questions or Comments about the article? Write to editor@tipranks.com